ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
February 22, 2024 16:05 ET | Ocugen
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Global Advanced Therapy Medicinal Products CDMO Market
Global Advanced Therapy Medicinal Products CDMO Market Analysis Report 2024-2030: : Increasing Investment and Clinical Trial Expenditure Driving Demand, Oncology Dominance and Emerging Treatment Areas
February 22, 2024 06:42 ET | Research and Markets
Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase,...
ocugen_4C_LOGO (002).png
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024 07:30 ET | Ocugen
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 ...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 12, 2024 08:00 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
United Kingdom Cell & Gene Therapy Cold Chain Logistics Market
UK Cell & Gene Therapy Cold Chain Logistics Market Analysis to 2028: Dominated by Atelerix, Life Science Group, and Cryoport UK
February 08, 2024 09:56 ET | Research and Markets
Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The "United Kingdom Cell & Gene Therapy Cold Chain Logistics Market, Competition, Forecast & Opportunities, 2028" report has been added to ...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
February 08, 2024 07:00 ET | Adverum Biotechnologies, Inc.
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and...
genenta logo positivo.png
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
February 08, 2024 05:00 ET | GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of...
market-digits.jpg
Advanced Therapy Medicinal Products Market to Accumulate a Valuation of USD 61.5 Billion by 2030, Advancing at a 13.4% CAGR | MarketDigits Richmond, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to a research report "Advanced Therapy Medicinal Products Market”, by Therapy Type (Cell Therapy {Stem Cell Therapy, Non-stem Cell Therapy},...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
February 05, 2024 07:45 ET | Adverum Biotechnologies, Inc.
- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare...
Adverum_Primary_Medium.png
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
February 01, 2024 17:30 ET | Adverum Biotechnologies, Inc.
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with...